DiscoverNew Retina Radio by EyetubeSwitching from Aflibercept to Faricimab in Wet AMD Patients
Switching from Aflibercept to Faricimab in Wet AMD Patients

Switching from Aflibercept to Faricimab in Wet AMD Patients

Update: 2024-12-19
Share

Description

Does switching wet AMD patients from aflibercept (Eylea, Regeneron) to faricimab (Vabysmo, Genentech) improve disease outcomes? Join Ben Young, MD, MS, and his guests Lediana Goduni, MD, and Joshua Uhr, MD, as they explore this a recent peer review paper on this question. What are the potential benefits of such a switch? How should providers use findings such as these to inform their practice? And are significant improvements in anatomy relevant if vision gains are unchanged? 

Comments 
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Switching from Aflibercept to Faricimab in Wet AMD Patients

Switching from Aflibercept to Faricimab in Wet AMD Patients

Retina Today

We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and our services, you agree to our use of cookies as described in our Cookie Policy.